Pharmacy Benefits and Disease-Modifying Therapies

<p><span data-sheets-value= "{"1":2,"2":"Dr. Justin Abbatemarco talks with Dr. Daniel Hartung about the association between Medicare Part D Plan disease-modifying therapy restrictiveness and adherence and outcomes among people with multiple sclerosis."}" data-sheets-userformat= "{"2":15359,"3":{"1":0},"4":{"1":2,"2":13624051},"5":{"1":[{"1":2,"2":0,"5":{"1":2,"2":0}},{"1":0,"2":0,"3":3},{"1":1,"2":0,"4":1}]},"6":{"1":[{"1":2,"2":0,"5":{"1":2,"2":0}},{"1":0,"2":0,"3":3},{"1":1,"2":0,"4":1}]},"7":{"1":[{"1":2,"2":0,"5":{"1":2,"2":0}},{"1":0,"2":0,"3":3},{"1":1,"2":0,"4":1}]},"8":{"1":[{"1":2,"2":0,"5":{"1":2,"2":0}},{"1":0,"2":0,"3":3},{"1":1,"2":0,"4":1}]},"9":0,"10":1,"11":4,"12":0,"14":{"1":3,"3":1},"15":"Calibri","16":11}"> Dr. Daniel Hartung discusses the association between Medicare Part D Plan disease-modifying therapy restrictiveness and adherence and outcomes among people with multiple sclerosis.</span></p> <p>Show references:</p> <p><a href= "https://cp.neurology.org/content/12/1/36">https://cp.neurology.org/content/12/1/36</a></p> <p>https://www.neurology.org/podcast</p>